These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27350411)

  • 21. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
    Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
    N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.
    Leary SES; Park JR; Reid JM; Ralya AT; Baruchel S; Wu B; Roberts TPL; Liu X; Minard CG; Fox E; Weigel B; Blaney S
    Clin Cancer Res; 2017 Oct; 23(20):6062-6069. PubMed ID: 28751444
    [No Abstract]   [Full Text] [Related]  

  • 24. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
    Mosoyan G; Kraus T; Ye F; Eng K; Crispino JD; Hoffman R; Iancu-Rubin C
    Leukemia; 2017 Nov; 31(11):2458-2467. PubMed ID: 28270692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
    Packer RJ; Rood BR; Turner DC; Stewart CF; Fisher M; Smith C; Young-Pouissant T; Goldman S; Lulla R; Banerjee A; Pollack I; Kun L; Onar-Thomas A; Wu S; Boyett JM; Fouladi M
    J Neurooncol; 2015 Jan; 121(1):217-24. PubMed ID: 25407389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
    Baerlocher GM; Oppliger Leibundgut E; Ottmann OG; Spitzer G; Odenike O; McDevitt MA; Röth A; Daskalakis M; Burington B; Stuart M; Snyder DS
    N Engl J Med; 2015 Sep; 373(10):920-8. PubMed ID: 26332546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
    Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R
    J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
    Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
    Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
    Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
    Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.
    Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G
    J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
    Gilheeney SW; Khakoo Y; Souweidane M; Wolden S; Boulad F; Dunkel IJ
    Pediatr Blood Cancer; 2010 Apr; 54(4):591-5. PubMed ID: 19998470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
    Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
    J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomerase inhibitors: a patent review (2010-2015).
    Man RJ; Chen LW; Zhu HL
    Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
    Shawi M; Chu TW; Martinez-Marignac V; Yu Y; Gryaznov SM; Johnston JB; Lees-Miller SP; Assouline SE; Autexier C; Aloyz R
    PLoS One; 2013; 8(7):e70428. PubMed ID: 23922990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
    Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z
    Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.
    Ferrandon S; Malleval C; El Hamdani B; Battiston-Montagne P; Bolbos R; Langlois JB; Manas P; Gryaznov SM; Alphonse G; Honnorat J; Rodriguez-Lafrasse C; Poncet D
    Mol Cancer; 2015 Jul; 14():134. PubMed ID: 26183089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of sunitinib malate in patients with recurrent high-grade glioma.
    Neyns B; Sadones J; Chaskis C; Dujardin M; Everaert H; Lv S; Duerinck J; Tynninen O; Nupponen N; Michotte A; De Greve J
    J Neurooncol; 2011 Jul; 103(3):491-501. PubMed ID: 20872043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
    Hummel TR; Salloum R; Drissi R; Kumar S; Sobo M; Goldman S; Pai A; Leach J; Lane A; Pruitt D; Sutton M; Chow LM; Grimme L; Doughman R; Backus L; Miles L; Stevenson C; Fouladi M; DeWire M
    J Neurooncol; 2016 Mar; 127(1):53-61. PubMed ID: 26626490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.
    Kadota RP; Stewart CF; Horn M; Kuttesch JF; Burger PC; Kepner JL; Kun LE; Friedman HS; Heideman RL
    J Neurooncol; 1999 May; 43(1):43-7. PubMed ID: 10448870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.